U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543198) titled 'Clinical Trial of PCV24 in Adults Aged >=18 Years' on April 14.
Brief Summary: A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged >=18 years.
The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, Positive Controlled phase Ib/II clinical trial.
Study Start Date: June 18, 2025
Study Type: INTERVENTIONAL
Condition:
Pneumococcal Infectious Disease
Intervention:
BIOLOGICAL: Sinovac Low-dosage PCV24
One dose of Sinovac Low-dosage PCV24 (0.5mL)
BIOLOG...